T Delate1, S J Coons. 1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson 85721-0207, USA. delate@pharmacy.arizona.edu
Abstract
BACKGROUND: Self-reported health-related quality of life (HRQOL) assesses constructs that transcend laboratory-based clinical parameters. Corroboration of the hypothesized relationships between the 2 types of health indicators (ie, clinical and HRQOL) could provide evidence of the validity of an HRQOL measurement tool. OBJECTIVE: The purpose of this study was to evaluate the ability of scores on the mental component summary (MCS-12) and physical component summary (PCS-12) of the 12-Item Short Form Health Survey (SF-12) to discriminate between HIV-infected persons in predefined disease-severity groups based on surrogate markers. METHODS: This cross-sectional study involved the collection of clinical data (ie, CD4 cell count, viral load [HIV-1 RNA copies/mL]) from patients' medical records and HRQOL data from the SF-12 at 2 HIV specialty clinics. The ability of SF-12 summary scores to discriminate between patients stratified by disease severity (ie, CD4 cell count <200 vs > or = 200/mm3; HIV-1 RNA >55,000 vs < or = 55,000 copies/mL) was assessed by receiver operating characteristic curve analysis. RESULTS: Data were collected from 478 patients. The scores from the PCS-12 were able to discriminate between groups of patients stratified by disease severity based on CD4 cell count (P < 0.001) and HIV-1 RNA copies/mL (P < 0.01). MCS-12 scores did not discriminate between disease-severity groups. CONCLUSIONS: Although the SF-12 is a brief generic measure of HRQOL, these findings provide further evidence of the validity of the SF-12 and suggest that it may be a practical way to monitor health status from the perspective of the HIV-infected patient.
BACKGROUND: Self-reported health-related quality of life (HRQOL) assesses constructs that transcend laboratory-based clinical parameters. Corroboration of the hypothesized relationships between the 2 types of health indicators (ie, clinical and HRQOL) could provide evidence of the validity of an HRQOL measurement tool. OBJECTIVE: The purpose of this study was to evaluate the ability of scores on the mental component summary (MCS-12) and physical component summary (PCS-12) of the 12-Item Short Form Health Survey (SF-12) to discriminate between HIV-infectedpersons in predefined disease-severity groups based on surrogate markers. METHODS: This cross-sectional study involved the collection of clinical data (ie, CD4 cell count, viral load [HIV-1 RNA copies/mL]) from patients' medical records and HRQOL data from the SF-12 at 2 HIV specialty clinics. The ability of SF-12 summary scores to discriminate between patients stratified by disease severity (ie, CD4 cell count <200 vs > or = 200/mm3; HIV-1 RNA >55,000 vs < or = 55,000 copies/mL) was assessed by receiver operating characteristic curve analysis. RESULTS: Data were collected from 478 patients. The scores from the PCS-12 were able to discriminate between groups of patients stratified by disease severity based on CD4 cell count (P < 0.001) and HIV-1 RNA copies/mL (P < 0.01). MCS-12 scores did not discriminate between disease-severity groups. CONCLUSIONS: Although the SF-12 is a brief generic measure of HRQOL, these findings provide further evidence of the validity of the SF-12 and suggest that it may be a practical way to monitor health status from the perspective of the HIV-infectedpatient.
Authors: Alexander C Tsai; Sheri D Weiser; Samantha E Dilworth; Martha Shumway; Elise D Riley Journal: Am J Epidemiol Date: 2015-03-31 Impact factor: 4.897
Authors: Isabel Cuéllar-Flores; Talía Saínz; Carlos Velo; María Isabel González-Tomé; Cristina García-Navarro; Carolina Fernández-Mcphee; Sara Guillén; José Tomás Ramos; Pilar Miralles; Rafael Rubio; José Ignacio Bernardino; Luis Prieto; Pablo Rojo; Santiago Jiménez de Ory; Maria Luisa Navarro Journal: World J Pediatr Date: 2019-07-08 Impact factor: 2.764
Authors: Kelly C Young-Wolff; Varada Sarovar; Stacy A Sterling; Amy Leibowitz; Brigid McCaw; Charles B Hare; Michael J Silverberg; Derek D Satre Journal: AIDS Care Date: 2019-03-19
Authors: Darren J Clayson; Diane J Wild; Paul Quarterman; Isabelle Duprat-Lomon; Maria Kubin; Stephen Joel Coons Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981
Authors: Nicolas Bertholet; Debbie M Cheng; Jeffrey H Samet; Emily Quinn; Richard Saitz Journal: Drug Alcohol Depend Date: 2010-06-25 Impact factor: 4.492
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731